ABSTRACT
We report two asymptomatic homozygotes for the nonsense p.R462X mutation affecting the carboxy-terminus of coagulation factor VII (FVII, 466 aminoacids). FVII levels of 3-5% and 2.7±0,4% were found in Prothrombin Time-based and activated factor X (FXa) generation assays with human thromboplastins. Noticeably, FVII antigen levels were barely detectable (0.7±0,2%), which suggested a gain-of-function effect. This effect was more pronounced with bovine thromboplastin (4.8±0,9%) and disappeared with rabbit thromboplastin (0.7±0,2%), thus pointing toward an influence of the mutation on Tissue Factor/FVII interactions.
Whereas the recombinant rFVII-462X variant confirmed an increased specific activity (~400%), a panel of nonsense (p.P466X, p.F465X, p.P464X, p.A463X) and missense (p.R462A, p.R462Q, p.R462W) mutations of the FVII carboxy-terminus resulted in reduced secretion but normal specific activity.
These data provide evidence for counteracting pleiotropic effects of the p.R462X mutation, which explains the asymptomatic FVII deficiency, and contributes understanding the role of the highly variable carboxy-terminus of coagulation serine proteases.
INTRODUCTION
The congenital deficiency of coagulation factor VII (FVII) (OMIM: 227500) is a rare haemorrhagic disorder with an autosomal recessive inheritance pattern. 1 The elucidation of the relationship between FVII coagulant activity levels in plasma and bleeding diathesis is greatly helped by the knowledge of the molecular mechanisms through which F7 gene mutations 2-3 modulate FVII levels.
Nonsense mutations, by inducing mRNA degradation 4 and/or premature termination of translation and synthesis of truncated proteins, are usually responsible for very severe forms of human diseases. As expected from the crucial role of FVII in coagulation, 5 this mutation type in homozygous patients are very few, and associated to undetectable FVII levels and severe [6] [7] [8] or moderate 9 bleeding.
Coagulation serine proteases share extensive homology 10 but are highly variable in their carboxy-terminal region, whose functional role is far from being established.
Here, we characterized the p.R462X nonsense mutation and provided evidence for its pleiotropic effects, i.e. reduced secretion and increased specific activity, thus explaining the asymptomatic phenotype in patients. Moreover, a panel of recombinant carboxyterminal variants contributed to understand the role of this highly variable region in coagulation serine proteases. 
DESIGN and METHODS

Patients
The proposita (PFVII-R462X) is a 12-year old girl, diagnosed for FVII deficiency during a routine coagulation screening. The patient presented with a prolonged prothrombin time (8%) and decreased FVII coagulant activity (3% and 5% of normal in two samples withdrawn 1 year apart), with normal activity of all the other coagulation factors. Her past and recent medical history was negative for any bleeding episode and she continues to be asymptomatic.
F7 gene sequencing 11 identified the c.1384C>T transition (GenBank #NM_000131.3) in homozygous condition, which results in the p.R462X nonsense mutation. The unrelated parents carried the mutation and showed half-reduced FVII levels.
Screening for F7 gene mutations identified the homozygous p.R462X mutation in an unrelated asymptomatic subject from France (male, 50 years old), who was diagnosed for FVII deficiency at 49 years of age during a preoperative screening. His FVII activity and antigen levels were 5% and <1% of normal respectively, and he has no bleeding history.
The research was part of a more extensive study on FVII deficient patients, which was approved by the Review Board of the University of Palermo (the original institution of G.M.). Moreover, the authors obtained informed consent from the proposita and her parents to conduct the study.
FVII activity and protein assays
FVII coagulant (FVIIc) levels were assessed by standard Prothrombin time (PT)-based assays by using RecombiPlasTin 2G (HemosIL TM , Instrumentation Laboratory, Lexington, MA, USA).
Calibrated automated thrombin activity measurement was conducted in accordance to
Hemker et al. 12 In these assays, TF was used at 5 pM concentration.
Generation of activated factor X (FXa) either in patient's plasma or with recombinant FVII variants was evaluated essentially as described. 13 As coagulation trigger we used either Inhibition by TFPI was assessed as previously described.
14 FVII antigen (FVIIag) levels in plasma or in conditioned medium were measured by ELISA (Affinity Biologicals TM Inc., Canada). In our hands, the detection limit was 1 ng/ml (0.2% of pooled normal plasma, PNP).
Western blotting was carried out essentially as previously reported 15 by exploiting the sheep polyclonal anti-human FVII HRP-conjugated antibody (Pierce, Thermo Scientific, Rockford, IL, USA).
Serial dilution of PNP or of rFVII-wt in FVII-deficient plasma (George King, Bio-Medical Inc., USA) were used to optimize all the assays for very low FVII levels.
As a reference for studies in plasma we used the PNP and expressed results as % to make easily comparable data across assays.
Expression vectors, cell culture and transfection
The mutations (underlined) were introduced into the human FVII cDNA cloned into the pCDNA3 vector 13 by using the QuickChange® II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and the following forward primers:
Reverse primers were perfectly complementary to the forward ones. Direct sequencing validated the vectors.
Baby hamster kidney (BHK) cells were cultured and transiently transfected in serum-free medium (Opti-MEM ® , GIBCO ® , Life Technologies, Carlsbad, CA, USA) as described. 13 The recombinant FVII (rFVII) in media were concentrated through the Amicon Ultra centrifugal filter devices (cut-off 30 KDa, Millipore, Carrigtwohill, Country Cork, Ireland).
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RESULTS AND DISCUSSION
The homozygous p.R462X nonsense mutation, predicting a FVII molecule with a truncated carboxy-terminus, was found in two unrelated subjects with no bleeding history and displaying appreciable and comparable FVIIc levels in plasma (3-5%). These coherent observations in homozygotes strongly suggest that the mutation is responsible for mild coagulation and clinical features. The previously identified heterozygous or doubly heterozygous subjects, [16] [17] did not allow evaluating the contribution of this mutation to FVII levels in vivo.
To detail the coagulation phenotype in the proposita's (PFVII-R462X) plasma we performed functional studies aimed at monitoring, upon extrinsic trigger, the generation of thrombin and of FXa. In these assays, we purposely included a plasma sample from a patient homozygous for the p.A354V-p.P464Hfs † mutation (PFVII-A354V-P464fs †), predicted to be responsible for a FVII molecule with an elongated carboxy-terminal region.
Homozygotes for this mutation showed low antigen and very low activity levels. As an informative variable to interpret the effects of FVII deficiency on thrombin generation, we considered the lag time since, among the other parameters (endogenous thrombin potential, time to peak), it better correlated to FVII levels ( Figure 1A , inset).
Through this analysis, the activity in PFVII-R462X and PFVII-A354V-P464fs † plasma samples was 1,5±0,1% and 0.25% of PNP, respectively ( Figure 1A ).
The FXa generation activity in the PFVII-R462X plasma upon triggering coagulation with
Innovin was clearly measurable (1.8±0,5% of PNP) whereas that in PFVII-A354V-P464fs † plasma was barely detectable (0.2±0.1%)( Figure 1B ).
In spite of the significantly different activities the FVII antigen levels in plasma from PFVII-R462X (0.7±0,2% of PNP) and PFVII-A354V-P464fs † (0.8%) were similarly reduced. This observation was further reinforced by Western blotting analysis ( Figure 1C , inset) that revealed only tiny amounts of FVII in PFVII-R462X and PFVII-A354V-P464fs † samples, with estimated levels below 1% of PNP.
To provide insights into the mechanism, we performed additional FXa generation assays in the proposita's plasma with different sources of TF and particularly RecombiPlasTin 2G, the recombinant human TF used in PT-based assays, and bovine or rabbit brain thromboplastins ( Figure 1C ).
The FXa generation activity with RecombiPlasTin 2G (2.7±0.4% of PNP; >3 times higher specific activity) was higher than that observed with Innovin, thus better mirroring the FVIIc levels. Interestingly, the highest activity was detected with bovine TF (4.8±0,9%), whereas the increased activity was no longer detectable with rabbit brain TF (0.7±0.2%).
Since the carboxyl-terminal residues of FVII might be involved in the recognition by inhibitors, as demonstrated for FXa 18 , we tested FVII inhibition in plasma by adding 2-4 U/ml Tissue Factor Pathway Inhibitor. However, we failed to demonstrate differences between proposita's plasma and PNP (not shown).
These results pointed toward the presence in PFVII-R462X's plasma of traces of a FVII variant with activity higher than normal.
The decreased amount of circulating protein could be theoretically attributed either to reduced FVII mRNA levels, through the nonsense mediated decay (NMD) mechanism, 4 and/or impaired protein biosynthesis. However, the introduction of a premature nonsense triplet in proximity of the natural termination signal (position 467) in the last exon, makes the occurrence of NMD very unlikely, thus supporting a major impact at the posttranslational level.
To experimentally address this issue, the p.R462X mutation was inserted into the human FVII cDNA (Figure 2A ) and expressed in BHK cells. While the FVII antigen levels of rFVIIwt in conditioned medium were 120±18 ng/ml, those of the rFVII-462X were virtually undetectable, thus mirroring the in vivo findings. On the other hand, the rFVII-462X levels in cell lysates (72±4.9%) were roughly comparable to those of rFVII-wt, thus excluding a preferential intracellular accumulation.
Interestingly, upon concentration of conditioned media by centrifugal devices, the rFVII-462X protein was detected both by ELISA (2.5±0.2 ng/ml) and Western blotting ( Figure   2B , inset), thus prompting us to evaluate its activity. Functional assays were conducted in plasma systems with human TF (Innovin) and by exploiting the FXa fluorogenic substrate, to better mimic the physiological conditions and to guarantee high sensitivity to very low activity levels. 6, 13 Compared to the activity (9.5±1.8 Rfu/sec/nM FVII) of a similar concentration of rFVII-wt, that of the rFVII-462X appeared to be approximately four times higher (36.3±8 Rfu/sec/nM FVII; 382%)( Figures 2B and 2C) . Overlapping results were obtained with RecombPlasTin 2G (440%) and bovine thromboplastin (400%), whereas the activity with rabbit thromboplastin was not appreciable.
Taken together, the coherent in vivo ( Figure 1C ) and in vitro ( Figure 2C , inset) findings support the association of the p.R462X mutation with traces of circulating FVII molecules with increased specific activity and gain-of-function features. This contributes to explain the asymptomatic phenotype observed in homozygous patients, throws light on a novel form of FVII deficiency and unravel original features of this highly heterogeneous disease.
By comparison, the p.R457X nonsense mutation in factor IX, lying five codons upstream of the natural stop codon as the p.R462X, was found to be associated to severe haemophilia B (FIXc <1% and FVIIag <1%). 19 The detrimental impact of the p.R462X mutation on secreted FVII levels is explained by the synthesis of truncated molecules lacking five residues at the carboxyterminal end. This region has been demonstrated to be essential for secretion of other coagulation serine protease family members such as factor IX 20 and protein C (PC), 21 whose carboxy-terminal variants displayed normal specific activity.
Although a recent study 17 on FVII supported a similar impact on protein secretion of sequential deletions in the carboxy-terminus up to the 462 position, their functional consequences are unknown. Therefore, we expressed the rFVII-466X, rFVII-465X and rFVII-464X variants (Figure 2A ) that resulted in secreted FVII molecules with progressively reduced antigen levels but virtually normal activity either in functional assays with Innovin ( Figure 2C ) or RecombiPlasTin 2G (not shown). Although expressed at extremely low levels, the rFVII-463X displayed a normal specific activity.
The increased activity observed in the presence of the p.R462X mutation could pertain to the truncated molecule, but also to traces of a full-length FVII variant resulting from ribosome readthrough, a process known to occur at very low (10 -3 -10 -4 ) rate. 22 In the latter case, the insertion at the nonsense position of aminoacids other than the natural one could alter biosynthesis, produce dysfunctional FVII variants, as we reported for the p.K376X and p.W424X mutations, 7 or elicit "gain-of-function" effects, so far never documented after readthrough. These novel and counteracting consequences on protein biosynthesis and function highlight the pleiotropic effects of natural mutations that, in addition to shaping patients' phenotype, could have contributed to the evolution and divergence of coagulation serine proteases, particularly in their highly variable carboxy-terminus.
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